- Home
- MGEE vs RCUS Comparison
MGEE vs RCUS Comparison
Compare MGEE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGEE | RCUS |
|---|---|---|
| Founded | 1855 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | 2001 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MGEE | RCUS |
|---|---|---|
| Price | $74.63 | $24.35 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $80.50 | $31.90 |
| AVG Volume (30 Days) | 357.6K | ★ 859.0K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 11.71 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $2.77 | $45.62 |
| P/E Ratio | $56.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $72.16 | $7.92 |
| 52 Week High | $90.66 | $28.72 |
Technical Indicators
Market Signals| Indicator | MGEE | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 50.37 |
| Support Level | $72.59 | $23.91 |
| Resistance Level | $81.89 | $26.70 |
| Average True Range (ATR) | 1.35 | 1.19 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 56.68 | 50.99 |
Price Performance
Historical ComparisonAbout MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.